Mizagliflozin is under clinical development by Kissei Pharmaceutical and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Mizagliflozin’s likelihood of approval (LoA) and phase transition for Constipation took place on 28 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Mizagliflozin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
mizagliflozin is under development for the treatment of chronic constipation. The drug candidate is orally administered. It targets selective inhibitor of sodium-dependent glucose cotransporter-1 (SGLT1). It was under development for treatment of type 2 diabetes.
Kissei Pharmaceutical overview
Kissei Pharmaceutical (Kissei) discovers, develops, manufactures, and sells a range of innovative pharmaceutical products. The company’s pharmaceutical products include urological medicine, metabolic endocrinology medicine, drugs for kidney and dialysis department, drugs for obstetrics and gynecology, ophthalmic medicine and rare disease medicine. It also develops and sells health foods including protein-controlled food, energy supply food, calorie-controlled food, and elderly controlled food. Kissei conducts research to develop novel drugs and improve existing drugs and provide superior drugs to people worldwide. The company has sales offices across Japan and an overseas subsidiary in New Jersey, the US. Kissei is headquartered in Matsumoto, Japan.
Quick View Mizagliflozin LOA Data
|Highest Development Stage|